This Article Full Text Full Text (PDF) All Versions of this Article: theoncologist.2008-0189v1 14/1/83    most recent eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, S. Y. Articles by Helman, L. J. Search for Related Content PubMed PubMed Citation Articles by Kim, S. Y. Articles by Helman, L. J.

Pediatric Oncology

The Role of IGF-1R in Pediatric Malignancies

^aPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; ^bLombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA

Key Words. IGF-1R • Pediatric malignancy • Molecular targeting • Therapeutic antibody

Correspondence: Su Young Kim, M.D., Ph.D., Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Building 10, CRC 1w-3750, Bethesda, Maryland 20892, USA. Telephone: 301-451-7018; Fax: 301-451-7010; e-mail: kimsuyou{at}mail.nih.gov

Received August 22, 2008; accepted for publication December 1, 2008; first published online in THE ONCOLOGIST Express on January 6, 2009.

Disclosures

Su Young Kim: None; Jeffrey A. Toretsky: None; Daniel Scher: None; Lee J. Helman: None

Section editors Susan M. Blaney and Ross Pinkerton have disclosed no financial relationships relevant to the content of this article.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.

Target audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in pediatric oncology.

The insulin-like growth factor (IGF) family consists of ligands (IGF-I, IGF-II, insulin), several receptors (including IGF-1R), and six binding proteins (IGFBP-1 through IGFBP-6). Members of this family regulate key cellular activities and they also play an important role in the development and progression of both adult and childhood cancers. Binding of a ligand to the receptor leads to its activation, followed by signal transduction along several pathways. In some childhood malignancies, IGF-1R can be activated by endocrine, autocrine, or paracrine mechanisms. Although mutations in IGF-1R have not been identified, this signaling pathway is upregulated in many childhood cancers. These findings have led to the development of a host of IGF-1R signaling modulators that are currently being tested in clinical trials. This review explores the role of IGF-1R in a range of childhood malignancies.

This article has been cited by other articles:

				M. S. Merchant and C. L. Mackall Current Approach to Pediatric Soft Tissue Sarcomas Oncologist, November 1, 2009; 14(11): 1139 - 1153. [Abstract] [Full Text] [PDF]

				Z. Duan, E. Choy, D. Harmon, C. Yang, K. Ryu, J. Schwab, H. Mankin, and F. J. Hornicek Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines Mol. Cancer Ther., August 1, 2009; 8(8): 2122 - 2130. [Abstract] [Full Text] [PDF]